Windlas Biotech
NSE: WINDLAS · Pharmaceuticals
Snapshot
Unlock Windlas Biotech's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Windlas Biotech Limited is a contract development and manufacturing organisation (CDMO) providing product discovery, development, and commercial manufacturing services. The company also maintains a portfolio of domestic trade generics and over-the-counter products across nutritional, ayurvedic, and wellness segments.
Business Model
The company generates revenue through B2B CDMO services for pharmaceutical and nutraceutical brands, alongside direct-to-market sales of its own trade generics and OTC products. Distribution is facilitated through a mix of offline retail channels and online e-commerce platforms.
Growth Outlook
Growth is driven by the expansion of its CDMO service offerings and the scaling of its domestic trade generics and OTC brand portfolio. The company continues to leverage its established export network across Southeast Asia, Africa, and the Caribbean to capture international demand.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical manufacturing regulations and quality standards, where non-compliance could lead to product recalls or facility shutdowns.
- Client Concentration. As a CDMO, the company relies on the commercial success and outsourcing strategies of its pharmaceutical brand partners.
- Market Competition. The domestic trade generics and OTC markets are highly fragmented and competitive, potentially impacting pricing power and margins.
- Geopolitical and Currency Risk. Exporting to diverse international markets exposes the company to fluctuations in foreign exchange rates and regional political instability.
Start your research today
Unlock AI insights, financials, peers and live data on Windlas Biotech and 5,000+ companies — free.
Key Metrics
REVENUE
₹942 Cr
TTM · standalone
NET PROFIT
₹66 Cr
TTM · standalone
EPS
₹31.63
TTM · standalone
RETURN ON EQUITY
12.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
16.8%
TTM · standalone
P/E
35.6x
Q1 FY27 · standalone
EV/EBITDA
19.6x
Q1 FY27 · standalone
EBITDA MARGIN
13.0%
TTM · standalone
NET PROFIT MARGIN
7.1%
Q1 FY27 · standalone
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Windlas BiotechWINDLAS | ₹2,377 Cr | 35.61 | 19.64 | 18.5% | 13.0% | 12.2% | 16.8% | +14.5% |
Beta Drugs LtdBETA | ₹2,459 Cr | — | — | — | 20.0% | — | — | +17.7% |
Fredun Pharmaceuticals LimitedFREDUN | ₹2,432 Cr | 20.00 | 27.39 | — | 14.9% | 21.3% | 40.9% | +15.0% |
Indoco RemediesINDOCO | ₹2,423 Cr | 820.34 | 20.29 | 12.1% | 9.0% | 0.3% | 8.4% | -3.9% |
Panacea BiotecPANACEABIO | ₹2,335 Cr | -328.66 | 130.32 | 10.3% | 2.6% | -1.1% | -0.4% | -6.4% |
Sai Parenterals LimitedSAIPARENT | ₹2,295 Cr | — | — | — | 10.0% | — | — | — |
As of Q1 FY27
Financials
Windlas Biotech
NSE: WINDLAS · Pharmaceuticals
Snapshot
Unlock Windlas Biotech's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Windlas Biotech Limited is a contract development and manufacturing organisation (CDMO) providing product discovery, development, and commercial manufacturing services. The company also maintains a portfolio of domestic trade generics and over-the-counter products across nutritional, ayurvedic, and wellness segments.
Business Model
The company generates revenue through B2B CDMO services for pharmaceutical and nutraceutical brands, alongside direct-to-market sales of its own trade generics and OTC products. Distribution is facilitated through a mix of offline retail channels and online e-commerce platforms.
Growth Outlook
Growth is driven by the expansion of its CDMO service offerings and the scaling of its domestic trade generics and OTC brand portfolio. The company continues to leverage its established export network across Southeast Asia, Africa, and the Caribbean to capture international demand.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical manufacturing regulations and quality standards, where non-compliance could lead to product recalls or facility shutdowns.
- Client Concentration. As a CDMO, the company relies on the commercial success and outsourcing strategies of its pharmaceutical brand partners.
- Market Competition. The domestic trade generics and OTC markets are highly fragmented and competitive, potentially impacting pricing power and margins.
- Geopolitical and Currency Risk. Exporting to diverse international markets exposes the company to fluctuations in foreign exchange rates and regional political instability.
Start your research today
Unlock AI insights, financials, peers and live data on Windlas Biotech and 5,000+ companies — free.
Key Metrics
REVENUE
₹942 Cr
TTM · standalone
NET PROFIT
₹66 Cr
TTM · standalone
EPS
₹31.63
TTM · standalone
RETURN ON EQUITY
12.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
16.8%
TTM · standalone
P/E
35.6x
Q1 FY27 · standalone
EV/EBITDA
19.6x
Q1 FY27 · standalone
EBITDA MARGIN
13.0%
TTM · standalone
NET PROFIT MARGIN
7.1%
Q1 FY27 · standalone
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27